Table 1 Patient and tumor characteristics
Total | 87 |
Age | 53 years (range: 28–83) |
Menopausal status | |
 pre-menopausal | 43 (50%) |
 peri-menopausal | 6 (7%) |
 post-menopausal | 38 (44%) |
T stadium pre-NACT | |
 cT1a-cT1c | 20 (23%) |
 cT2 | 51 (59%) |
 >cT2 | 14 (16%) |
 Unknown | 2 (2%) |
T stadium post-NACT | |
 ypT0, ypTis | 18 (21%) |
 ypT1a | 11 (13%) |
 ypT1b, ypT1c | 18 (21%) |
 ypT2 | 26 (30%) |
 >ypT2 | 10 (12%) |
 Unknown | 4 (5%) |
N stadium pre-NACT | |
 cN0 | 41 (47%) |
 cN1 | 40 (46%) |
 cN2, cN3 | 5 (6%) |
 Unknown | 1 (1%) |
N stadium post-NACT | |
 yN0 | 47 (54%) |
 yN1 | 29 (33%) |
 yN2/N3 | 8 (9%) |
 Unknown | 3 (4%) |
Tumor type | |
 Ductal invasive | 60 (69%) |
 Lobular invasive | 11 (13%) |
 Other | 14 (16%) |
 Unknown | 2 (2%) |
Tumor grade | |
 G1 | 4 (5%) |
 G2 | 40 (46%) |
 G3 | 42 (48%) |
 Unknown | 1 (1%) |
Estrogen receptor (IHC)a | |
 Positive | 68 (78%) |
 Negative | 19 (22%) |
Progesterone receptor (IHC)a | |
 Positive | 58 (67%) |
 Negative | 29 (33%) |
HER2 a | |
 Positive | 23 (26%) |
 Negative | 64 (74%) |
Tumor subtype | |
 ER-, PR-, HER2- | 14 (16%) |
 ER-, PR-, HER2+ | 4 (5%) |
 ER+/PR+, HER2- | 50 (58%) |
 ER+, PR+, HER2+ | 19 (22%) |
NACT regimen | |
 CTX | 53 (61%) |
 CTX + Trastuzumab | 14 (16%) |
 CTX + Avastin | 4 (5%) |
 CTX + Lapatinib + Trastuzumab | 6 (7%) |
 HTX | 9 (10%) |
 Unknown | 1 (1%) |
Trastuzumab treatment | |
 Yes | 20 (23%) |
 No | 66 (76%) |
 Unknown | 1 (1%) |
Clinical response | |
 pCR | 15 (17%) |
 pPR | 62 (71%) |
 pNC | 6 (7%) |
 Unknown | 4 (5%) |
Histological tumor regression gradeb | |
 0 | 6 (7%) |
 1 | 32 (37%) |
 2 | 22 (25%) |
 3 | 5 (6%) |
 4 | 12 (14%) |
 Unknown | 10 (12%) |
Local treatment | |
 Mastectomy | 56 (64%) |
 Breast conservation surgery | 26 (30%) |
 Unknown | 5 (6%) |
DTC positive | |
 pre-NACT | 16 (18%) |
 post-NACT | 13 (15%) |